What is MS Phase 3 Study Teriflunomide (HMR1726) TOWER?

Category: Others

false

See also: Clinical Trial

NCT00751881 is a multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of the drug teriflunomide in patients with relapsing multiple Sclerosis. Other study IDs include: TOWER, EFC10531, EudraCT: 2007-004452-36.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
1
None
1

Commonly reported side effects and conditions associated with MS Phase 3 Study Teriflunomide (HMR1726) TOWER

Side effect Patients

Why patients stopped taking MS Phase 3 Study Teriflunomide (HMR1726) TOWER

Multiple reasons could be selected

Reason Patients
Course of treatment ended 1
See 1 patient who's stopped using MS Phase 3 Study Teriflunomide (HMR1726) TOWER

Duration

Stopped using MS Phase 3 Study Teriflunomide (HMR1726) TOWER

Duration Patients
2 - 5 years 1
Adherence
Adherence Evaluations
Always 2
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 2
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 2
Not specified 0
Last updated:
There are no evaluations for MS Phase 3 Study Teriflunomide (HMR1726) TOWER.